Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

Sergio Ricci; Giuseppe Boni; Ilaria Pastina; Dario Genovesi; Claudia Cianci; Serena Chiacchio; Cinzia Orlandini; Mariano Grosso; Abedallatif AlSharif; Aldo Chioni; Samantha Di Donato; Francesco Francesca; Cesare Selli; Domenico Rubello; Giuliano Mariani

首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

【24h】

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

机译：153 Sm-EDTMP骨靶向放射代谢疗法联合化学疗法治疗转移性激素难治性前列腺癌的临床疗效

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Bone metastases are responsible for most of the morbidity associated with hormone-refractory prostate cancer (HRPC). 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) has been approved for palliation of painful skeletal metastases. We retrospectively investigated the possible synergistic effect on survival of 153Sm-EDTMP (given to HRPC patients for bone pain palliation) and chemotherapy.

机译：骨转移是与激素难治性前列腺癌（HRPC）相关的大多数发病率的原因。 153 Ss-乙二胺四亚甲基膦酸酯（153 Sm-EDTMP）已被批准用于缓解疼痛的骨骼转移。我们回顾性研究了153 Sm-EDTMP（给予HRPC患者缓解骨痛的效果）和化疗对生存的可能协同作用。

著录项

来源
《European Journal of Nuclear Medicine and Molecular Imaging》 |2007年第7期|1023-1030|共8页
作者
Sergio Ricci; Giuseppe Boni; Ilaria Pastina; Dario Genovesi; Claudia Cianci; Serena Chiacchio; Cinzia Orlandini; Mariano Grosso; Abedallatif AlSharif; Aldo Chioni; Samantha Di Donato; Francesco Francesca; Cesare Selli; Domenico Rubello; Giuliano Mariani;
展开▼
作者单位

Division of Medical Oncology Department of Oncology University Hospital Pisa Italy;

Regional Center of Nuclear Medicine University of Pisa Medical School Via Roma 67 56126 Pisa Italy;

Division of Medical Oncology Department of Oncology University Hospital Pisa Italy;

Regional Center of Nuclear Medicine University of Pisa Medical School Via Roma 67 56126 Pisa Italy;

Division of Medical Oncology Department of Oncology University Hospital Pisa Italy;

Regional Center of Nuclear Medicine University of Pisa Medical School Via Roma 67 56126 Pisa Italy;

Division of Medical Oncology Department of Oncology University Hospital Pisa Italy;

Regional Center of Nuclear Medicine University of Pisa Medical School Via Roma 67 56126 Pisa Italy;

Regional Center of Nuclear Medicine University of Pisa Medical School Via Roma 67 56126 Pisa Italy;

Division of Medical Oncology Department of Oncology University Hospital Pisa Italy;

Division of Medical Oncology Department of Oncology University Hospital Pisa Italy;

Division of Urology University Hospital Pisa Italy;

Section of Urology Department of Surgery University of Pisa Medical School Pisa Italy;

Nuclear Medicine Service-PET Center “S. Maria della Misericordia” Hospital Rovigo Italy;

Regional Center of Nuclear Medicine University of Pisa Medical School Via Roma 67 56126 Pisa Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Hormone-refractory prostate cancer; 153Sm-EDTMP; Chemotherapy; Combination therapy; Clinical benefit;

机译：激素难治性前列腺癌;153Sm-EDTMP;化学疗法;联合疗法;临床获益;

相似文献

外文文献
中文文献
专利

1. Clinical benefit of bone-targeted radiometabolic therapy with (153)Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. [J] . Ricci S, Boni G, Pastina I, European Journal of Nuclear Medicine and Molecular Imaging . 2007,第7期

机译：（153）Sm-EDTMP骨靶向放射代谢疗法联合化疗对转移性激素难治性前列腺癌患者的临床益处。
2. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. [J] . Cella D, Nichol MB, Eton D, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2009,第1期

机译：为前列腺癌的功能评估评估临床上有意义的变化：转移性激素难治性前列腺癌患者的临床试验结果。
3. Re: Liselotte MS Boeve, Maarten CCM Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019; 75: 410-8 Future Steps for Definitive Therapy in Metastatic Prostate Cancer: Lessons from the HORRAD Trial [J] . Shinde Ashwin, Li Richard, Amini Arya, European urology . 2019,第3期

机译：Re：Liselotte Ms Boeve，Maarten CCM Hulshof，Andre N. Vis等人。与雄激素剥夺治疗相比，对雄激素剥夺治疗的生存对雄激素剥夺治疗与前瞻性随机临床试验中原发性骨转移前列腺癌前列腺患者的同时剥夺治疗的影响：来自血腥审判的数据。 EUR UROL 2019; 75：410-8转移性前列腺癌中的明确治疗的未来步骤：来自血轮试验的教训
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. The Effects of Adjuvant Chemotherapy on Brain Function in Breast Cancer Patients and a Cancer-Chemotherapy Rodent Model. [D] . Barr, Alicia Thomas. 2014

机译：辅助化疗对乳腺癌患者脑功能的影响和癌症化学疗法的啮齿动物模型。
6. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases [O] . Marnix G. E. H. Lam, Amel Dahmane, Wil H. M. Stevens, -1

机译：唑来膦酸和153Sm-EDTMP在激素难治性前列腺癌骨转移患者中的联合使用
7. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases [O] . Lam, Marnix G. E. H., Dahmane, Amel, Stevens, Wil H. M., 2007

机译：唑来膦酸和153Sm-EDTMP在激素难治性前列腺癌骨转移患者中的联合使用

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅